8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.

Effect of Terahertz Waves on the Structure of the Aβ42 Monomer, Dimer, and Protofibril: Insights from Molecular Dynamics Simulations

Bioeffects Seen

Chen C, Yan Z-S Ma Y-Q, Ding H-M · 2023

Share:

Specific terahertz wave frequencies can structurally alter amyloid-beta peptides in ways that enhance their aggregation and stabilization, raising potential concerns about electromagnetic field exposure.

Plain English Summary

Summary written for general audiences

This molecular dynamics simulation study investigated how terahertz waves affect the structure of amyloid-beta (Aβ42) peptides at different aggregation states. The researchers found that terahertz waves at 42.55 THz enhanced structural interactions in Aβ42 monomers and dimers by resonating with specific molecular vibration modes, increasing β-sheet content and binding energy between monomers, while also mildly stabilizing tetrameric protofibril structures.

Why This Matters

This is a computational study using molecular dynamics simulations rather than experimental research, so findings represent theoretical predictions about protein-field interactions. Amyloid-beta aggregation is implicated in Alzheimer's disease pathology, making the structural effects observed here potentially relevant to neurodegenerative disease mechanisms, though further experimental validation would be needed.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Chen C, Yan Z-S Ma Y-Q, Ding H-M (2023). Effect of Terahertz Waves on the Structure of the Aβ42 Monomer, Dimer, and Protofibril: Insights from Molecular Dynamics Simulations.
Show BibTeX
@article{chen_c_yan_z_s_ma_y_q_ding_h_m_ce3181,
  author = {Chen C and Yan Z-S Ma Y-Q and Ding H-M},
  title = {Effect of Terahertz Waves on the Structure of the Aβ42 Monomer, Dimer, and Protofibril: Insights from Molecular Dynamics Simulations},
  year = {2023},
  doi = {10.1016/j.annonc.2023.09.3108},
  
}

Quick Questions About This Study

This appears to be a database classification error. The study examines pharmaceutical cancer treatments with no electromagnetic field content or relevance to EMF health research.
No, these are pharmaceutical drugs administered intravenously and orally for kidney cancer treatment. The study contains no electromagnetic field exposure or EMF-related measurements.
None whatsoever. This is purely a pharmaceutical clinical trial comparing drug efficacy for renal cell carcinoma with no electromagnetic field components or considerations.
While hospitals use EMF-emitting equipment, this study focused solely on drug effectiveness and safety outcomes without measuring or considering electromagnetic field exposure.
No, this study provides no EMF-related data or insights. It belongs in oncology research databases, not electromagnetic field health research collections.